European Medicines Agency Reorganizes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Medicines Agency Reorganizes


The European Medicines Agency (EMA) has released details about its restructuring. The reorganization, first announced in December 2012 and expected to be completed in 2014, focuses on supporting scientific work of the various EMA committees, sharing information throughout the European Union’s regulatory system, and meeting the needs of stakeholders and partners.

The new structure introduces an operating model for managing drugs through their entire lifecycle, with separation of the scientific and procedure management. EMA will increase the number and complexity of applications being handled by the Agency’s committees to reinforce the robustness and quality of the Agency’s output. The reorganization creates four new divisions: Human Medicines Research and Development Support, Human Medicines Evaluation, Procedure Management and Business Support, and Inspections and Human Medicines Pharmacovigilance. A new Division for Stakeholders and Communication will provide improved coordination of the Agency’s relations with patients and healthcare professionals, support for small and medium-sized enterprises, and a dedicated communication service.

“The changes announced today will reshape the EMA so that it is ready to handle future challenges and seize opportunities,” said Professor Guido Rasi, EMA Executive Director in a press release. “My aim is to give our scientific committees the best possible support, alongside the expertise from the national agencies, to help them keep delivering high-quality, consistent opinions. These changes will enable us to use our resources more efficiently and effectively and ensures that the Agency is better prepared for future legislative and policy challenges.”

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
26%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here